Illustrative image – not actual.
Aurobindo Pharma has commissioned four manufacturing plants for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), injectable products and granulation, through its wholly-owned subsidiaries.
The Penicillin-G (Pen-G) facility, located in a SEZ at Kakinada in Andhra Pradesh, has a production capacity of 15,000 tpa, along with 1.8 lakh tonne of gulcose, while 6-amino penicillanic acid plant has a capacity to produce 3,600 tonne annually.
The Rs 2,400 crore Pen-G plant is expected to start trial production in April, 2024 and commercial production in the next two months. Production ramp-up is slated for the second quarter of the current financial year. The plant was approved under the production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country.
The injectable plant has the capacity to produce 285 million vials/ampoules annually and the granulated products plant will produce 13,200 tonne annually.
